Oragenics (OGEN)
(Delayed Data from AMEX)
$1.27 USD
+0.25 (24.51%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $1.28 +0.01 (0.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Oragenics, Inc. [OGEN]
Reports for Purchase
Showing records 1 - 20 ( 39 total )
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Oral Mucositis Phase 2 Primary Efficacy Endpoint Missed; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
2019 Financial Results; Phase 2 Oral Mucositis Data Coming Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Oral Mucositis Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Oral Mucositis Study Blinded Interim Data Presented at ESMO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Enrollment Milestone Reached in Oral Mucositis Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Enrollment Update on Phase 2 Trial of Dapatifagene Navolactibac; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Preventing Oral Mucositis With Resistance-Evading Antibiotics as a Second Act; Initiating at Buy and $2 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
We are terminating coverage of Oragenics Inc. due to reallocation of resources.
Provider: DIAMOND EQUITY RESEARCH LLC
Analyst: DIAMOND H
Company: Oragenics, Inc.
Industry: Medical - Biomedical and Genetics
Enrollment Continues With AG013 Top Line Results Anticipated in Early 2020
Provider: DIAMOND EQUITY RESEARCH LLC
Analyst: DIAMOND H